Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,528
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,195.50 | 10.00 | 0.12% |
| CAC 40 | 7,916.08 | 74.03 | -0.93% |
| DAX 40 | 22,461.52 | 217.22 | -0.96% |
| Dow JONES (US) | 41,583.90 | 715.80 | -1.69% |
| FTSE 100 | 8,658.85 | 7.27 | -0.08% |
| HKSE | 23,426.60 | 152.20 | -0.65% |
| NASDAQ | 17,322.99 | 481.04 | -2.70% |
| Nikkei 225 | 37,120.33 | 679.64 | -1.80% |
| NZX 50 Index | 12,287.46 | 18.33 | -0.15% |
| S&P 500 | 5,580.94 | 112.37 | -1.97% |
| S&P/ASX 200 | 7,982.00 | 13.00 | 0.16% |
| SSE Composite Index | 3,351.31 | 22.44 | -0.67% |